Compare PASG & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PASG | ICMB |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 30.7M |
| IPO Year | 2020 | 2013 |
| Metric | PASG | ICMB |
|---|---|---|
| Price | $5.90 | $1.86 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 109.2K | 64.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 29.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.29 |
| 52 Week High | $20.00 | $3.12 |
| Indicator | PASG | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 46.95 |
| Support Level | N/A | $1.60 |
| Resistance Level | $8.65 | $3.00 |
| Average True Range (ATR) | 1.33 | 0.16 |
| MACD | -0.46 | 0.05 |
| Stochastic Oscillator | 2.54 | 61.93 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.